Form 4: Intellia Therapeutics Executive Sells Shares to Cover Tax Obligations

Intellia Therapeutics' EVP, Chief Business Officer, Derek Hicks, sold 6,502 shares of common stock to cover tax obligations related to vesting of restricted stock units.

Summary

• Derek Hicks, EVP and Chief Business Officer at Intellia Therapeutics, sold 6,502 shares of common stock on January 3, 2025.
• The sale was executed at a price of $12.18 per share.
• This transaction was a mandatory 'sell-to-cover' to satisfy tax withholding obligations from the vesting of restricted stock units (RSUs).
• The sale does not represent a volitional trade by Mr. Hicks.
• Following the transaction, Mr. Hicks beneficially owns 59,878 shares of Intellia Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's outlook or performance.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice for executives receiving stock-based compensation.
• The number of shares sold is relatively small compared to the total outstanding shares of the company.
• Similar transactions are regularly reported by executives at other publicly traded biotech companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the company's outlook or performance.

Key Dates

Keywords

Intellia Therapeutics, Insider Trading, SEC Form 4, Stock Sale, Derek Hicks, Tax Obligations, RSU Vesting, Executive Compensation